title: [HE4 a biomarker of ovarian cancer].
abstract: OBJECTIVE
  Verification of the importance of determination of HE4 and calculation of ROMA index for increasing the efficiency of diagnosis of ovarian cancer in a population of Czech women.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Department of Gynaecology and Obstetrics, Faculty Hospital in Pilsen.
  
  
  METHODS
  In the period from 06/24/2010 to 12/01/2011 was at the Department of Gynaecology and Obstetrics, University Hospital Pilsen examined 552 patients with abnormalities in the pelvis. Patients were divided into two groups. There were 30 women with histologically confirmed malignant ovarian tumors. Another 522 women had benign findings. According to the levels of FSH were women in both groups divided into premenopausal and postmenopausal. At all women were measured CA 125, HE4 and FSH. HE4 and CA125 were determined using the chemiluminescent device Architect 1000 (Abbott, USA), FSH chemiluminescent method on the device DXI 800 (Beckman Coulter, USA). At all premenopausal women was calculated ROMA1 index and at all postmenopausal women ROMA2 index. SAS statistical software 9.2 were used for all statistical calculations.
  
  
  RESULTS
  The highest diagnostic efficiency was achieved by a combination of HE4 and CA125 markers with the calculation ROMA2 index for postmenopausal women. In determining of menopausal status according to the values of FSH cut-off for menopause 40 IU/L and cut-off at 26.4% for ROMA2 reaches ROMA2 sensitivity of 92.3%, specificity of 88.5% and PV- of 99.3%. If we reduce the cut-off for laboratory diagnosis of menopause using FSH at 22 IU/L, and cut-off for ROMA2 was 26.3% reaches ROMA2 sensitivity of 95.2%, specificity of 87.8% and PV- of 99.5%.
  
  
  CONCLUSIONS
  HE4 in combination with CA125 and current ROMA index calculation is a suitable methodology to improve the detection of ovarian cancer.
authors.affiliation: Gynekologicko-porodnická klinika LF UK a FN Plzen, prednosta doc. MUDr. Z. Novotný, CSc. jiri.presl77@seznam.cz
authors.forename: J
authors.initials: J
authors.lastname: Presl
authors.forename: R
authors.initials: R
authors.lastname: Kučera
authors.forename: O
authors.initials: O
authors.lastname: Topolčan
authors.forename: Z
authors.initials: Z
authors.lastname: Novotný
authors.forename: J
authors.initials: J
authors.lastname: Vrzalová
authors.forename: R
authors.initials: R
authors.lastname: Fuchsova
authors.forename: L
authors.initials: L
authors.lastname: Betincová
authors.forename: Z
authors.initials: Z
authors.lastname: Rokyta
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D011237:Predictive Value of Tests; D011506:Proteins / Q000032:analysis*; D012680:Sensitivity and Specificity; D000081102:WAP Four-Disulfide Core Domain Protein 2
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human